Compugen (NASDAQ:CGEN) Coverage Initiated by Analysts at Lake Street Capital

Equities research analysts at Lake Street Capital initiated coverage on shares of Compugen (NASDAQ:CGEN) in a report released on Tuesday,Benzinga reports. The firm set a “buy” rating and a $6.00 price target on the biotechnology company’s stock. Lake Street Capital’s price target would suggest a potential upside of 175.23% from the stock’s previous close.

CGEN has been the subject of several other reports. Wall Street Zen raised Compugen from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Truist Financial raised Compugen to a “strong-buy” rating in a research report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compugen in a research report on Wednesday, January 21st. Finally, HC Wainwright assumed coverage on Compugen in a research report on Wednesday, January 7th. They set a “buy” rating and a $4.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Compugen has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Compugen Trading Down 3.5%

NASDAQ CGEN opened at $2.18 on Tuesday. Compugen has a 12 month low of $1.13 and a 12 month high of $2.38. The firm has a market capitalization of $206.12 million, a P/E ratio of 5.89 and a beta of 2.77. The business has a fifty day simple moving average of $1.96 and a 200 day simple moving average of $1.79.

Compugen (NASDAQ:CGEN) last announced its earnings results on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.55. Compugen had a return on equity of 55.68% and a net margin of 48.57%.The firm had revenue of $67.33 million during the quarter, compared to analyst estimates of $14.30 million. As a group, sell-side analysts predict that Compugen will post -0.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Compugen

Several large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in Compugen in the 4th quarter worth about $104,000. Bank Hapoalim BM purchased a new stake in Compugen in the 4th quarter worth about $37,000. Security National Bank of Sioux City Iowa IA purchased a new stake in Compugen in the 4th quarter worth about $38,000. Marshall Wace LLP increased its holdings in Compugen by 135.7% in the 4th quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 61,202 shares during the last quarter. Finally, State Street Corp increased its holdings in Compugen by 3.9% in the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock worth $603,000 after acquiring an additional 14,701 shares during the last quarter. Hedge funds and other institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.